RESEARCH ARTICLE

Low diagnostic yield and time to diagnostic confirmation results in prolonged use of antimicrobials in critically ill children [version 2; peer review: 2 approved, 1 approved with reservations]

John Clark¹,², Deborah White², Esther Daubney², Martin Curran³, Rachel Bousfield², Theodore Gouliouris², Elizabeth Powell², Adam Palmer², Shruti Agrawal², David Inwald¹, Iain Kean¹, M. Estée Török²,⁴,⁵, Stephen Baker⁵, Nazima Pathan¹,²

¹Department of Paediatrics, University of Cambridge, Cambridge, Cambridgeshire, CB2 0QQ, UK
²Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, CB2 0QQ, UK
³Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, Cambridgeshire, CB2 0QQ, UK
⁴Department of Medicine, University of Cambridge, Cambridge, Cambridgeshire, CB2 0QQ, UK
⁵Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, Cambridgeshire, CB2 0QQ, UK

Abstract
Background: Broad-spectrum antimicrobial therapy is a key driver of antimicrobial resistance. Here, we aimed to review indications for antimicrobial therapy, determine the proportion of suspected bacterial infections that are confirmed by culture, and assess the time taken for microbiology test results to become available in the paediatric intensive care unit (PICU).

Methods: A single-centre prospective observational cohort study of 100 consecutive general PICU admissions from 30 October 2019 to 19 February 2020. Data were collected from the hospital medical record and entered into a study database prior to statistical analysis using standard methods.

Results: Of all episodes of suspected infection, 22% of lower respiratory tract infection, 43% of bloodstream and 0% of central nervous system infection were associated with growth on microbiology culture. 90% of children received antimicrobial therapy. Hospital-acquired infection occurred less commonly than primary infection, but an organism was grown in a greater proportion (64%) of cultures. Final laboratory reports for negative cultures were issued at a median of 120.3 hours for blood cultures and 55.5 hours for endotracheal tube aspirate cultures.

Open Peer Review

Approval Status ✔ ✔ ?

version 2 (revision)
03 Mar 2022 view view view

version 1
18 May 2021 view view view

1. Arne Simon, University Hospital of Saarland, Homburg, Germany
2. Sanjay Patel, The British Society for Antimicrobial Chemotherapy, Birmingham, UK
3. Ahmed El-Nawawy, Alexandria University, Alexandria, Egypt
Conclusions: Despite most critically children receiving antimicrobial therapy, infection was often not microbiologically confirmed. Novel molecular diagnostics may improve rationalisation of treatment in this population.

Keywords
Paediatric intensive care units, infections, anti-infective agents, microbial drug-resistance, microbiological techniques, routine diagnostic tests

Corresponding author: John Clark (jac302@cam.ac.uk)

Author roles: Clark J: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Software, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; White D: Data Curation, Investigation, Writing – Review & Editing; Daubney E: Data Curation, Investigation, Writing – Review & Editing; Curran M: Writing – Review & Editing; Bousfield R: Writing – Review & Editing; Gouliouris T: Writing – Review & Editing; Powell E: Data Curation, Investigation, Writing – Review & Editing; Palmer A: Data Curation; Agrawal S: Writing – Review & Editing; Inwald D: Writing – Review & Editing; Kean I: Writing – Review & Editing; Torok ME: Conceptualization, Methodology, Writing – Review & Editing; Baker S: Conceptualization, Funding Acquisition, Methodology, Resources, Supervision, Writing – Review & Editing; Pathan N: Conceptualization, Funding Acquisition, Methodology, Resources, Software, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Wellcome Trust [215515] (SB); the Gates Cambridge Trust (JC); the Academy of Medical Sciences (MET); Addenbrooke's Charitable Trust, Cambridge University Hospitals [900240] (NP, JC, MET, SB); the NIHR Cambridge Biomedical Research Centre; and Action Medical Research (NP, SB, MET). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2022 Clark J et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Clark J, White D, Daubney E et al. Low diagnostic yield and time to diagnostic confirmation results in prolonged use of antimicrobials in critically ill children [version 2; peer review: 2 approved, 1 approved with reservations] Wellcome Open Research 2022, 6:119 https://doi.org/10.12688/wellcomeopenres.16848.2

First published: 18 May 2021, 6:119 https://doi.org/10.12688/wellcomeopenres.16848.1
Introduction

The annual number of infections caused by antimicrobial resistant (AMR) organisms in England is ≥70,000. Optimised prescribing practice has been highlighted as a key national strategy to combat AMR. However, it is challenging for clinicians to reduce the use of broad spectrum antimicrobials when faced with severe and undifferentiated illness encountered in the paediatric intensive care unit (PICU). The timely administration of antimicrobials is paramount, as survival decreases 7.6% for every hour antimicrobial therapy is delayed in patients with septic shock. Clinical prediction scores for infection perform poorly in children, and there is a reliance on diagnostic tests to assist in rationalisation of antimicrobial therapy. Here we aimed to better understand the impact of microbiology results and antimicrobial prescribing in a PICU in a major UK tertiary referral centre as previous reports have been limited to descriptive and exploratory nature of the study. All admitted patients were reviewed for eligibility during the enrolment period. The primary indication for admission was determined through daily screening of various structures and staffing of other hospitals. In addition, this inter-hospital transfer notes, and documented communications between PICU and the referring hospital. All documented investigations to a maximum period of one week prior to PICU admission were included in this study. Turnaround times in addition to microbiology rounds that take place twice a week. Broadly, first line treatment for severe community acquired pneumonia is ceftriaxone (for children aged greater than one month) with consideration of atypical cover with azithromycin or clarithromycin. Co-amoxiclav is used for aspiration pneumonia, and piperacillin-tazobactam for suspected ventilator associated pneumonia. Community acquired septicaemia is treated with ceftriaxone and gentamicin (in children greater than one month) whilst piperacillin-tazobactam and gentamicin is used for children with hospital-acquired septicaemia. Ceftriaxone or cefotaxime is the first line treatment for community acquired meningitis, with the addition of aciclovir for encephalitis.

Methods

This study included 100 patients admitted to the PICU at Cambridge University Hospitals NHS Foundation Trust between 30 October 2019 and 19 February 2020. The sample size was based on the estimated number of ventilated PICU admissions based on previous PICANet data over a four month study period. This allowed completion of this project prior to commencement of an interventional study relating to rapid diagnostic testing (Rapid Assay for Sick Children with Acute Lung infection Study, ClinicalTrials.gov: NCT04233268, 18/01/2020). Formal sample size calculation was not indicated given the descriptive and exploratory nature of the study. All admitted patients were reviewed for eligibility during the enrolment period. Patients were identified by daily screening of the electronic medical record (Epic, Verona, USA) by the lead, medically qualified author by reviewing the active PICU admission patient list.

Data were entered into a study database formatted for this project on an electronic data capture system (REDCap 9.5.19) hosted by University of Cambridge. This database allowed data to be checked at the time of entry through customisation of accepted data into fields, for example, placing permissible date-time ranges for entry only during the intended study period. The project was registered on the Addenbrooke’s Hospital Quality and Safety Information System (QSIS, project ID 2606, 13 November 2019). This registration facilitated internal review within the hospital, and the project was authorised as a clinical audit. As no identifiable patient data or intervention was a component of the study, this authorised the project to take place and ethics review was not required. Given data was de-identified, waiver of consent was approved in this review.

Patients were eligible for inclusion in the study if they received mechanical ventilation via an endotracheal tube (ETT) during their admission and were aged ≥37 weeks corrected gestation at the time of enrolment. These criteria were used to avoid inclusion of patients who were not critically unwell and receiving high dependency level care only, and patients that would have otherwise gone to neonatal intensive care except for capacity and cohorting related reasons. Antimicrobial decision making in this institution is directed by internal prescribing guidelines produced by the antimicrobial stewardship team (available on request from lead author), with deviation from these guidelines on consultation with the microbiology team and review of investigations and the clinical situation. Broadly, first line treatment for severe community acquired pneumonia is ceftriaxone (for children aged greater than one month) with consideration of atypical cover with azithromycin or clarithromycin. Co-amoxiclav is used for aspiration pneumonia, and piperacillin-tazobactam for suspected ventilator associated pneumonia. Community acquired septicaemia is treated with ceftriaxone and gentamicin (in children greater than one month) whilst piperacillin-tazobactam and gentamicin is used for children with hospital-acquired septicaemia. Ceftriaxone or cefotaxime is the first line treatment for community acquired meningitis, with the addition of aciclovir for encephalitis.
pneumonia (VAP) if antimicrobial therapy for lower respiratory tract infection (LRTI) was commenced ≥48 hours following PICU admission. This definition was selected because of the known poor specificity of paediatric diagnostic scores for VAP. Sepsis was defined as per the Goldstein criteria. A suspected infection was defined by the commencement of antimicrobial therapy by the clinical team. Each type of suspected infection was evaluated individually due to the issues of secondary infection, multi-compartment infection and new infections occurring through the admission to PICU.

Statistical analysis was performed using SPSS (version 24)\(^\text{11}\). Simple descriptive statistics were used to describe counts and percentages. Given non-normality of the datasets, median and interquartile range were reported.

**Results**

**Baseline patient characteristics**

Between 18 November 2019 and 19 February 2020 there were 210 admissions to the PICU. Of these, three were excluded because their age was <37 weeks corrected gestational age and 107 were excluded because they did not require mechanical ventilation. Of the 100 admissions that fulfilled the inclusion criteria, 78 were single admissions and 22 were re-admissions\(^\text{12}\). There were 55 (71%) male patients, comprising 61 (61%) of admissions. The median age was 11.2 months (interquartile range (IQR), 2.2 to 58.0 months). The median weight was 8.0kg (IQR, 4.1 to 20.4kg). There were 94 emergency admissions and six elective admissions. The majority of patients were direct transfers to PICU from external hospitals (n = 66) with the remainder being from the Emergency Department (n = 14), transfers from the wards (n = 11) and Theatre and Recovery Area (n = 9). The median Paediatric Index of Mortality 3 (PIM3) score\(^\text{13}\) was 0.97 (IQR, 0.46 to 3.49). The median length of stay in the PICU was five days (IQR, two to eight days), with a total 747 PICU admission days; 94% of children survived and were discharged.

**Patients with suspected and confirmed infection**

Respiratory problems were responsible for 49% of admissions, of which 63% had bronchiolitis, 18% pneumonia, 10% structural airway problems, 4% asthma, 2% congenital diaphragmatic hernia, and 2% mediastinal mass (Table 1). The most common indications for commencing antimicrobials within 48 hours of admission were suspected LRTI (52%), central nervous system (CNS) (29%) and bloodstream infection (19%) (Table 2). The number of episodes of treatment exceeds the number of admissions due to some patients having multi-organ infection such as sepsis secondary to LRTI. For some patients, whilst an infection was treated it did not represent the primary indication for admission to PICU. Microbiological culture confirmed the presence of a bacterial or fungal organism in 17% of cases of suspected LRTI and 37% of cases of suspected bloodstream infection. No microbiological diagnosis was made for other suspected primary infections.

PICU-acquired infection occurred less commonly (n = 14), but a bacterial isolate was identified in a greater proportion of HAIs than community-acquired infections. (Table 2). There were seven instances of hospital-acquired pneumonia (six ventilator-associated pneumonia) of which four were associated with a bacterial isolate. This equates to a suspected ventilator-associated pneumonia rate of 10.3 per 1000 ventilator days (6 cases for 580 days of mechanical ventilation). There were two episodes of treatment for presumed bloodstream infection, and three episodes of presumed line infection, all with positive microbiological cultures. This equates to a central line infection rate of 7.8 per 1000 central line days (3 cases from 383 central line days).

There were no positive cultures in patients with suspected CNS infection (n = 1) or skin and soft tissue infection (n = 1).

**Performance of microbiology and virology investigations prior to PICU admission**

Of the 100 PICU admissions, 50 had microbiology and virology tests obtained prior to PICU admission. This encompassed 81 investigations for infection. The most common investigations were blood culture (35/81 tests) and nasopharyngeal aspirate for respiratory viruses (25/81 tests) (Table 3).

**Performance of microbiology and virology investigations undertaken during PICU admission**

Of the 93 admissions in which cultures were performed, 81 (87%) had samples collected in the PICU following antimicrobial therapy, five (5%) had samples taken before antimicrobial therapy, and seven (8%) had a culture taken before and after antimicrobial therapy. The most common samples were ETT
aspirates, blood and cerebrospinal fluid (Table 4). The median times for the laboratory to report the organism identity and antimicrobial susceptibilities for ETT aspirates and blood cultures were 55.0 hours and 102.5 hours, respectively. There were insufficient samples in the study to provide summary data for time to organism identity and susceptibility for urine specimens. The median times for a final report of no growth on cultures from time of receipt of specimens were 55.5 and 120.3 hours for ETT aspirates and blood cultures, respectively.

Respiratory virus PCR results were returned after a median 21.7 hours on ETT aspirates, 21.6 hours on nasopharyngeal aspirates (NPA) and 24.4 hours on nasopharyngeal (NP) swabs. Of the respiratory samples tested for viruses, a pathogen was detected in 74% of tests, of which respiratory syncytial virus (RSV) was the most common (Table 5). The most commonly detected bacterial species on ETT aspirate culture and Non-Bronchoscopic Bronchoalveolar Lavage (NB-BAL) were Staphylococcus aureus (11% of admissions), Pseudomonas aeruginosa (5%), Enterobacter cloacae (3%), coagulase-negative staphylococci (2%) and Moraxella catarrhalis (2%). Other species identified included Acinetobacter pittii, Citrobacter freundii, Enterococcus species, Escherichia coli, Haemophilus influenzae, Bordetella pertussis, Pseudomonas chloroaphis,

| Table 2. Proportion of suspected infections treated with antimicrobial therapy confirmed by growth on culture. |
|---------------------------------------------------------------|
| **Type of suspected infection treated with antimicrobial therapy** | **Culture site** | **Growth on culture/Total episodes of treatment (%)** |
| Blood stream | Blood culture | 7/19 (37) | 2/2 (100) | 9/21 (43) |
| Central nervous system | Cerebrospinal fluid | 0/29 (0) | 0/1 (0) | 0/30 (0) |
| Intra-abdominal | Aspirate of collection | 0/3 (0) | 0/0 (0) | 0/3 (0) |
| Line | Line tip | 0/0 (0) | 3/3 (100) | 3/3 (100) |
| Lower respiratory | Tracheal aspirate | 9/52 (17) | 4/7 (57) | 13/59 (22) |
| Soft tissue | Wound swab | 0/2 (0) | 0/1 (0) | 0/3 (0) |
| **Total** | | 16/105 (15) | 9/14 (64) |

PICU, paediatric intensive care unit.

| Table 3. Microbiology and virology tests obtained prior to PICU admission. |
|---------------------------------------------------------------|
| **Test** | **Number of samples** | **Tested positive n (%)** |
| Blood culture | 35 | 5 (14) |
| CSF culture | 5 | 0 |
| CSF viral PCR | 1 | 0 |
| ETT aspirate culture | 1 | 1 (100) |
| Fluid culture (intra-abdominal) | 1 | 0 |
| NPA viral PCR | 25 | 23 (92) |
| NP swab viral PCR | 9 | 6 (67) |
| Sputum culture | 3 | 2 (67) |
| Wound swab culture | 1 | 1 |
| **Total** | 81 | 38 (47) |

NP Nasopharyngeal; NPA: nasopharyngeal aspirate; CSF: cerebrospinal fluid; PCR: polymerase chain reaction; ETT: endotracheal tube; PICU: paediatric intensive care unit.
**Table 4. Microbiology tests and turn-around times.**

| Test                | Number of samples | Tested positive n(%) | Time in hours from laboratory receipt of specimen to organism identity and bacterial susceptibilities (median, IQR) | Time in hours from laboratory receipt of specimen to final report of a negative result (median, IQR) |
|---------------------|-------------------|-----------------------|----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Blood culture       | 79                | 8 (10)                | 55.0 (43.5 – 72.0)                                                                                               | 120.3 (120.2 – 121.0)                                                                         |
| CSF culture         | 41                | 0 (0)                 | N/A                                                                                                               | 44.2 (42.0 – 49.9)                                                                             |
| CSF viral PCR       | 25                | 0 (0)                 | N/A                                                                                                               | 39.3 (26.4 – 41.2)                                                                             |
| ETT aspirate culture| 85                | 30 (35)               | 102.5 (74.8 – 153.5)                                                                                            | 55.5 (50.9 – 71.1)                                                                             |
| ETT viral PCR       | 20                | 10 (50)               | 21.7 (19.7 – 23.4)                                                                                               | 55.0 (38.2 – 64.6)                                                                             |
| NPA viral PCR       | 79                | 62 (78)               | 21.6 (15.2 – 25.7)                                                                                               | 23.6 (21.1 – 24.5)                                                                             |
| NP swab viral PCR   | 20                | 16 (80)               | 24.4 (20.2 – 29.3)                                                                                               | 23.3 (17.2 – 26.5)                                                                             |
| Urine culture       | 39                | 4 (10)                | *                                                                                                                 | 5.7 (2.7 – 13.8)                                                                              |
| **Total**           | **388**           | **130 (34)**          |                                                                                                                   |                                                                                                |

ETT: endotracheal tube; IQR: interquartile range; N/A: not applicable; NPA: nasopharyngeal aspirate; CSF: cerebrospinal fluid; PCR, polymerase chain reaction. * Insufficient sample size.

**Table 5. Viral pathogens detected on respiratory samples.**

| Virus                              | Endotracheal tube viral PCR N = 20 | Nasopharyngeal aspirate viral PCR N = 79 | Nasopharyngeal swab viral PCR N = 20 | Total N = 119 |
|------------------------------------|-----------------------------------|---------------------------------------|--------------------------------------|---------------|
| Respiratory syncytial virus        | 8                                 | 33                                    | 7                                    | 48            |
| Rhinovirus                         | 2                                 | 17                                    | 6                                    | 25            |
| Enterovirus                        | 0                                 | 8                                     | 3                                    | 11            |
| Adenovirus                         | 1                                 | 6                                     | 2                                    | 9             |
| Human metapneumovirus              | 0                                 | 5                                     | 4                                    | 9             |
| Parainfluenza                      | 0                                 | 4                                     | 0                                    | 4             |
| Picornaviruses (undifferentiated)   | 1                                 | 2                                     | 1                                    | 4             |
| Influenza A                        | 1                                 | 2                                     | 0                                    | 3             |
| **Total pathogen detections**      | **13**                            | **77**                                | **23**                               | **113**       |
| **Any pathogen detected on test**  | **10 (50%)**                      | **62 (78%)**                          | **16 (80%)**                         | **88 (74%)**  |

PCR: polymerase chain reaction.

**Staphylococcus haemolyticus, Staphylococcus hominis and Streptococcus pyogenes.**

At least one antimicrobial was administered prior to 72/100 PICU admissions and during 90/100 PICU admissions. An antimicrobial was given within the first 24 hours of admission in 83% of cases, and within 24 hours of discharge for 50% of admissions. To determine total antimicrobial use, proportion of days on antimicrobial therapy were calculated per days of admission to PICU. Antimicrobials were given for a median 66.7% of days of PICU admission (IQR, 34.6 to 100%). The most commonly prescribed antimicrobials on PICU included beta-lactams (57.7%), macrolides (19.9%) and aminoglycosides (10.7%) (Table 6).

**Discussion**

This study provides insight into antimicrobial prescribing practice and microbiology investigations in a general PICU in a tertiary referral centre in the East of England. The report is unique as previous studies describing microbiology tests...
### Table 6. Days of antimicrobial therapy by class given to critically ill children.

| Antimicrobial class     | Total days of treatment | Proportion of total days of PICU admission (%) | Antimicrobial class | Total days of treatment* | Proportion of total days of PICU admission (%) |
|-------------------------|-------------------------|-----------------------------------------------|---------------------|--------------------------|-----------------------------------------------|
| Aminoglycoside          | 80                      | 10.7                                          | Gentamicin          | 38                       | 5.1                                           |
|                         |                         |                                               | Tobramycin          | 43                       | 5.8                                           |
| Beta-lactam             | 431                     | 57.7                                          | Amoxicillin         | 4                        | 0.5                                           |
|                         |                         |                                               | Benzylpenicillin    | 14                       | 1.9                                           |
|                         |                         |                                               | Cefotaxime          | 19                       | 2.5                                           |
|                         |                         |                                               | Ceftazidime         | 25                       | 3.3                                           |
|                         |                         |                                               | Ceftolozane-tazobactam | 17                   | 2.3                                           |
|                         |                         |                                               | Ceftriaxone         | 210                      | 28.1                                          |
|                         |                         |                                               | Co-amoxiclav        | 22                       | 2.9                                           |
|                         |                         |                                               | Fludoxacillin       | 35                       | 4.7                                           |
|                         |                         |                                               | Meropenem           | 53                       | 7.1                                           |
|                         |                         |                                               | Piperacillin-tazobactam | 88                   | 11.8                                          |
| Fluoroquinolone         | 31                      | 4.1                                           | Ciprofloxacin       | 31                       | 4.1                                           |
| Glycopeptide            | 37                      | 5.0                                           | Vancomycin          | 37                       | 5.0                                           |
| Macrolide               | 149                     | 19.9                                          | Azithromycin        | 43                       | 5.8                                           |
|                         |                         |                                               | Clarithromycin      | 114                      | 15.3                                          |
| Other                   | 64                      | 8.6                                           | Chloramphenicol     | 7                        | 0.9                                           |
|                         |                         |                                               | Clindamycin         | 11                       | 1.5                                           |
|                         |                         |                                               | Co-trimoxazole      | 12                       | 1.6                                           |
|                         |                         |                                               | Colomycin           | 8                        | 1.1                                           |
|                         |                         |                                               | Doxycycline         | 1                        | 0.1                                           |
|                         |                         |                                               | Linezolid           | 1                        | 0.1                                           |
|                         |                         |                                               | Metronidazole       | 10                       | 1.3                                           |
|                         |                         |                                               | Mupirocin           | 14                       | 1.9                                           |
| **Total**               | **792**                 |                                               | **857**             |                          |                                               |

PICU: paediatric intensive care unit. *Note – 20 children were prescribed more than one antimicrobial of the same class on the same day leading to a discrepancy between total number of days of treatment by individual antimicrobial and antimicrobial class.

and antimicrobial prescribing in critically ill children do not provide a detailed overview of practice for the entire PICU admission. It demonstrates that the majority of ventilated children admitted to PICU receive antimicrobial therapy in the absence of a positive microbiological culture. Of the combined primary and PICU-acquired infections, a bacterial isolate was identified in just 21%. This is consistent with European point prevalence data of paediatric prescribing, which suggest 25.7% of hospital antimicrobial prescriptions are tailored towards known pathogen identity\textsuperscript{4}. In a UK PICU surveillance study, proven infection was found in <7% of children treated with antimicrobials\textsuperscript{15}. Given existing clinical prediction scores are unreliable in PICU, it is important for diagnostic tests to be evaluated.

Microbiological culture techniques are labour-intensive, time consuming, and can take several days to yield a result. In this study, a final negative report was issued at a median of 55.5 hours for ETT aspirate and at 120.3 hours for blood cultures. PICU prescribers will often wait 24–48 hours for any
preliminary microbiology findings prior to changing or ceasing antimicrobial treatment. This is reflected in the fact that antimicrobial therapy was administered in 66.7% of all days of PICU admission. For example, the majority of patients admitted to PICU for primary neurological reasons were intubated for status epilepticus; however, it is difficult for clinicians to identify which of these patients have meningoencephalitis, which although uncommon may be catastrophic if untreated. Faster tests to rule out severe infection could reduce the total doses patients require of antimicrobial therapy.

Antimicrobial use was influenced by the high proportion (52%) of admissions treated for severe acute LRTI. Of these admissions, there was growth on ETT aspirate culture in just 17%. This low yield may be due to a number of factors including the sampling technique, prior antimicrobial therapy and limitations of microbiology culture. The routine sampling technique for LRTI culture was ETT aspirate. The unit has now shifted towards NB-BAL sampling as this has been demonstrated to have a higher yield and to be a well-tolerated sampling technique. Cultures may also be negative due to no bacteria being present, hence the value of fast turnaround highly sensitive tests for early cessation of antimicrobial therapy.

VAP occurred in six (6%) of the patients equating to 10.3 cases per 1000 ventilator days, a similar prevalence to another UK study. This was the most common PICU-acquired infection, which was also the case in a previous three-year retrospective study on this unit. Of admissions with VAP, four had positive cultures. This is a higher proportion than for primary LRTI, but a larger sample size is needed to demonstrate statistical difference between groups. An organism was identified in 57% of episodes of treatment for PICU-acquired LRTI, similar to the 55.6% detection rate in a previous study.

Our study is limited by being undertaken in a single centre. The data are likely to under-report presence of bacterial and fungal pathogens and AMR given the limitations of routine culture in detecting pathogens. Microbiology culture performance was likely limited due to the majority of samples in PICU being obtained after antimicrobial therapy, albeit culture yield was also low in pre-PICU samples which are typically obtained prior to antimicrobial therapy in clinical practice. Therefore, the threshold for treatment and factors contributing to commencement of treatment are important to understand. It would be ideal for future studies to occur in multiple centres and over a longer study duration to obtain a better profile of pathogens identified in PICUs in this region.

Conclusions
Antimicrobials are frequently prescribed in our centre’s PICU for presumed bacterial infection. Bacterial culture has a long turnaround time and may fail to identify potential bacterial pathogens, particularly where antimicrobial therapy is commenced prior to culture. In contrast, in viral PCR testing, a virus was identified in 74% of respiratory samples obtained. Rapid novel bacterial molecular diagnostic techniques could assist clinicians in making a microbiological diagnosis and rationalising broad spectrum antimicrobial therapy earlier. Early, tailored antimicrobial therapy is key to good antimicrobial therapy and the global fight against AMR.

Data availability
Underlying data
Open Science Framework: Paediatric intensive care prescribing and infection investigations cohort study. https://doi.org/10.17605/OSF.IO/C6WUS52.

This project contains the following underlying data:
- Raw data file.CSV
- Data dictionary.CSV

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

References

1. Public Health England: English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR). Public Health England. 2019. Reference Source
2. HM Government: Tackling antimicrobial resistance 2019-2024; The UK’s five-year national action plan. 2019. Reference Source
3. Kumar A, Roberts D, Wood KE, et al.: Duration of Hypotension before Initiation of Effective Antimicrobial Therapy Is the Critical Determinant of Survival in Human Septic Shock. Crit Care Med. 2006; 34(6): 1589-1596. PubMed Abstract | Publisher Full Text
4. da Silva PS, de Aguiar VE, de Carvalho WB, et al.: Value of clinical pulmonary infection score in critically ill children as a surrogate for diagnosis of ventilator-associated pneumonia. J Crit Care. 2014; 29(4): 545-550. PubMed Abstract | Publisher Full Text
5. Sachdev A, Chugh K, Sethi M, et al.: Clinical Pulmonary Infection Score to diagnose ventilator-associated pneumonia in children. Indian Pediatr. 2011; 48(12): 949-954. PubMed Abstract | Publisher Full Text
6. Paediatric Intensive Care Audit Network: Paediatric Intensive Care Audit Network Annual Report 2019. 2019. Reference Source
7. Harris PA, Taylor R, Minor BL, et al.: The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95: 103208. PubMed Abstract | Publisher Full Text | Free Full Text
8. Harris PA, Taylor R, Thielke R, et al.: Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009; 42(2): 377-81. PubMed Abstract | Publisher Full Text | Free Full Text
9. Public Health England: Standards for microbiology investigations (UK SMI). UK Standards for Microbiology Investigations (UK SMIs) are a comprehensive...
10. Goldstein B, Giroir B, Randolph A, et al.: International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005; 6(1): 2-8.

11. IBM Corp: IBM SPSS Statistics for Macintosh, Version 26. 2019.

12. Clark JA: Paediatric intensive care prescribing and infection investigations cohort study. 2021. http://www.doi.org/10.17605/OSF.IO/C6WU5

13. Straney L, Clements A, Parslow RC, et al.: Paediatric index of mortality 3: an updated model for predicting mortality in pediatric intensive care*. Pediatr Crit Care Med. 2013; 14(7): 673-681.

14. Versporten A, Biegelj J, Drapier N, et al.: The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children. J Antimicrob Chemother. 2016; 71(4): 1106-1117.

15. Stocker M, Ferrao E, Banya W, et al.: Antibiotic surveillance on a paediatric intensive care unit: easy attainable strategy at low costs and resources. BMJ Pediatric. 2012; 12: 196.

16. Khilnani GC, Arafath TK, Hadda V, et al.: Comparison of bronchoscopic and non-bronchoscopic techniques for diagnosis of ventilator associated pneumonia. Indian J Crit Care Med. 2011; 15(1): 16-23.

17. Telles JN, Richard N, Gillet Y, et al.: Viral and bacterial pathogens identification in children hospitalised for severe pneumonia and parapneumonic empyema. Pneumonia (Nathan). 2012; 1: 11-19.

18. Boots RJ, Phillips GE, George N, et al.: Surveillance culture utility and safety using low-volume blind bronchoalveolar lavage in the diagnosis of ventilator-associated pneumonia. Respirology. 2008; 13(1): 87-96.

19. Ismail N, Darbyshire A, Thorburn K: Ventilator-associated pneumonia (VAP): a UK PICU experience. Arch Dis Child. 2012; 97(1): A153.3–A154.

20. Akinkugbe O, Cooke FJ, Pathan N: Healthcare-associated bacterial infections in the paediatric ICU. JAC Antimicrob Resist. 2020; 2(3): dista056.
Open Peer Review

Current Peer Review Status: ✔ ✔ ❓

Version 2

Reviewer Report 07 March 2022

https://doi.org/10.21956/wellcomeopenres.19579.r48995

© 2022 Patel S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✔ Sanjay Patel

The British Society for Antimicrobial Chemotherapy, Birmingham, UK

Many thanks to the authors for responding to the comments that I made. I agree that a study looking into the impact of a multiplex bacterial and viral panel on PICU may be helpful in improving AMS in this setting. I look forward to seeing the results of their study.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Antimicrobial stewardship and AMR

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 04 March 2022

https://doi.org/10.21956/wellcomeopenres.19579.r48994

© 2022 Simon A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✔ Arne Simon

Pediatric Hematology and Oncology, Children's Hospital Medical Center, University Hospital of Saarland, Homburg, Germany

Many thanks for the revised version, no further comments.

Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Pediatric infectious diseases, Nosocomial infection in pediatric patients. Antimicrobial stewardship.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 22 December 2021

https://doi.org/10.21956/wellcomeopenres.18583.r47294

© 2021 El-Nawawy A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ahmed El-Nawawy
Department of Pediatrics, Faculty of Medicine, Alexandria University, Alexandria, Egypt

I read with great interest and enthusiasm the manuscript published by John Clark and his colleagues. I also read carefully the valuable comment of Dr Simon and I do agree with her scientific queries. I do believe that this type of informative research should be presented to the Pediatric community in general and to the PICU community more specifically. This research pointed out to the importance of using newer molecular diagnostic multiplex PCR in microbiological diagnosis to reduce the turnover time, which I think that most of us are using by now this technique in PICU.

Here is my additional observations and queries to be added to those of Dr Simon:

1. I hoped that the setting in which the study is performed to be described shortly.

2. A “RECORD” algorithm could be more representative, although all the necessary data in this context are mentioned. This simply could be replaced.

3. I agree with your statement in the introduction that one hour delay in antimicrobial therapy would reduce survival by 7.6%; so I am just asking why you did not use rapid molecular multiplex PCR in bacterial diagnosis and used it for viral diagnosis?

4. I agree with you that NB-BAL is better than ETT aspirate in microbiological diagnosis, I think in most of PICUs it is a routine by now. Is it possible to add this to your recommendations?

5. The number of viral detections and bacterial detections explained that there must be patients having “mixed infections” which is very common in PICUs. I hope that it will be able to have a table differentiating the three groups: viral, bacterial and mixed, and which is which (which is simply colonization and how to speculate the causative organism).
6. 72/100 patients received antibiotics prior to admission to PICU, and only 50 patients had microbiology and virology tests prior to PICU admission: does this mean that the 22 patients received empirical antibiotics according to the hospital ASP and did not perform any test until PICU admission?

7. Why did molecular viral PCR being reported after 21-25 hours while most of the PCR techniques report in one hour or less according to available machine?

8. It is better to report infections per device day.

9. I repeat the observation of Dr Simon concerning table 6 where B-Lactam is in a separate row and the members of the same group are in separate rows i.e carbapenem and cephalosporin. Usually groups are compared with classes and classes are compared with classes.

10. The authors reported 21 resistant samples of them 8 patients had MDR resistant organisms, but from table 7 all MDR were 2 organisms at different sites (no XDR & PDR). What is important I to know the resistant genes which carry a significant importance on epidemiological basis. This again emphasizes the importance of multiplex PCR which detects not only the organism but their resistant genes. I have to ask how you managed these resistant organisms.

11. In page 8 the author discussed the difficulty in diagnosing meningoencephalitis. I can't see why a CSF PCR for bacteria and viruses detection in 45-60 minutes as well as a confirmative MRI will not do.

12. Mortality: I expected to find a statistical analysis for the “Risk factors” of mortality if possible. Moreover it was reported only the PICU mortality and not the 30 days mortality. To conclude this is an outstanding work, we all seek for perfections. I hope that all the reviewers’ observations could be considered in re-publication which this manuscript deserves.

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
Yes

**Are all the source data underlying the results available to ensure full reproducibility?**
No source data required

**Are the conclusions drawn adequately supported by the results?**
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Reviewer expertise: Pediatric Intensive Care – Sepsis & septic shock – Pediatric Infections & in factious disease in PICU – Fluid & Electrolyte management in PICU – Pediatric Mechanical Ventilation.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 28 Feb 2022

John Clark, University of Cambridge, Cambridge, UK

The authors thank Dr El-Nawawy for the review and address it as follows:

This research pointed out to the importance of using newer molecular diagnostic multiplex PCR in microbiological diagnosis to reduce the turnover time, which I think that most of us are using by now this technique in PICU.

We disagree that the use of multiplex PCR to detect bacterial as well as viral infection is widespread in well-resourced PICU settings, let alone globally. We are aware of routine use of commercially available respiratory multiplex PCR panels that include several viruses, but these have a limited number of atypical bacterial organisms eg. Pertussis and Haemophilus incorporated. On reviewing the literature, we have not identified any centres that are routinely using panels that include a wider range of bacterial targets, hence this requires further evaluation.

A “RECORD” algorithm could be more representative, although all the necessary data in this context are mentioned. This simply could be replaced.

Thank you for the suggestion, we have reviewed the manuscript against the STROBE checklist for observational studies and attempted to address all recommended points.

I agree with your statement in the introduction that one hour delay in antimicrobial therapy would reduce survival by 7.6%; so I am just asking why you did not use rapid molecular multiplex PCR in bacterial diagnosis and used it for viral diagnosis?

Multiplex PCR testing for a variety of commonly detected bacterial organisms is not routinely available in this institution. In the setting of respiratory infection however, it is subject to an ongoing evaluation in this centre.

I agree with you that NB-BAL is better than ETT aspirate in microbiological diagnosis, I think in most of PICUs it is a routine by now. Is it possible to add this to your recommendations? We disagree – most centres do not undertake NB-BAL routinely, and the procedure was introduced to improve the reliability of the assay during this study. However it must also be noted that the study was not sufficiently powered to evaluate the performance of sampling via NB-BAL versus ETT aspirate, given this collection method was introduced following this project.
The number of viral detections and bacterial detections explained that there must be patients having “mixed infections” which is very common in PICUs. I hope that it will be able to have a table differentiating the three groups: viral, bacterial and mixed, and which is which (which is simply colonization and how to speculate the causative organism).

This study represents a range of indications for admission and subsequent treatment. On CSF samples, no child had a positive test result on microbiology or virology. In addition there were no blood-borne viruses detected. Therefore, we focus here on groupings of patients according to respiratory diagnostic tests. 58/100 patients had both microbiology (any of ETT aspirate/pleural aspirate/NB-BAL culture) and virology testing (any of NP swab, NPA or ETT viral respiratory panel) performed. Of these patients, 36 (62%) had viral detection only, 6 (10%) had bacterial detection only, 11 (19%) had mixed cause and the remaining 5 (9%) had no respiratory microorganism identified. Due to the range of patients in the cohort it is challenging to stratify likelihood of the true cause of illness. For example, for children that were more severely unwell and perhaps immunsuppressed there is a lower threshold for intervention and significance attached to investigations compared to a previously well child.

**72/100 patients received antibiotics prior to admission to PICU, and only 50 patients had microbiology and virology tests prior to PICU admission: does this mean that the 22 patients received empirical antibiotics according to the hospital ASP and did not perform any test until PICU admission?**

Dr El-Nawawy is correct in this. Some children have not had cultures performed prior to PICU admission despite receiving antibiotics due to administration for surgical prophylaxis or the fact that transfers to PICU may have been time critical eg. Traumatic brain injury, where there was not sufficient time for referring teams to obtain cultures prior to transfer.

**Why did molecular viral PCR being reported after 21-25 hours while most of the PCR techniques report in one hour or less according to available machine?**

Point of care molecular viral PCR testing is unavailable in this PICU and samples are sent to the diagnostic laboratory. Turnaround time is limited by staffing of this service. Of note, in the setting of the SARS-CoV-2 pandemic, all lower respiratory samples (ETT aspirate and NB-BAL) were initially handled in a containment level 3 laboratory before being split for further microbiological and virology investigations.

**It is better to report infections per device day.**

Rates of BSI and VAP have been added to the manuscript (Results -> Patients with suspected and confirmed infection).

**I repeat the observation of Dr Simon concerning table 6 where B-Lactam is in a separate row and the members of the same group are in separate rows i.e carbapenem and cephalosporin. Usually groups are compared with classes and classes are compared with classes.**

Thank you. Table 6 has been updated to classify antimicrobials more clearly.

**The authors reported 21 resistant samples of them 8 patients had MDR resistant**
organisms, but from table 7 all MDR were 2 organisms at different sites (no XDR & PDR). What is important to know the resistant genes which carry a significant importance on epidemiological basis. This again emphasizes the importance of multiplex PCR which detects not only the organism but their resistant genes. I have to ask how you managed these resistant organisms.

As per reviewer 3 request the table has been removed. We provide some information regarding management of resistant isolates to our reply to reviewer 1. AMR gene testing is not routinely available in this institution however for unusual isolates, samples can be sent to a national reference laboratory. Only one sample in this cohort was sent to the national reference laboratory however it was unable to be processed.

In page 8 the author discussed the difficulty in diagnosing meningoencephalitis. I can't see why a CSF PCR for bacteria and viruses detection in 45-60 minutes as well as a confirmative MRI will not do.

In this centre meningitis and encephalitis are diagnosed clinically, in addition to testing of blood and CSF. Cell counts on CSF are available within hours of sampling to assist initial rationalisation of treatment however CSF viral PCR testing in this cohort took a median of 39.3 hours. Bacterial PCR of CSF is not routinely available. Neuroimaging would only be performed if there were atypical features related to the presentation, or to investigate for raised intracranial pressure prior to lumbar puncture. This would usually be via CT. MRI is not undertaken routinely due to resources both in the radiology department and having a PICU team available to transport the ventilated patient. In addition it would be unlikely to change management unless undertaken to identify an alternative cause of the patient's presentation.

Mortality: I expected to find a statistical analysis for the “Risk factors” of mortality if possible. Moreover it was reported only the PICU mortality and not the 30 days mortality.

The focus of the present study was to identify performance of diagnostic tests and describe antimicrobial use in the PICU. The study was not sufficiently powered to undertake an analysis of risk factors for mortality due to the patient group being heterogenous whilst the mortality rate in PICU was low at 6%. It was not possible to determine the 30-day mortality due as this would have required the researchers to contact the patients' families – which was not permissible when the study was registered as an audit (approved internally).

Clark, J. A. et al. Rapid Assay for Sick Children with Acute Lung infection Study (RASCALS): diagnostic cohort study protocol. BMJ Open 11, e056197 (2021).

**Competing Interests:** No competing interests were disclosed.
The authors aim to address the extremely important topic of antimicrobial stewardship in severely unwell children admitted to PICU. The study was conducted between 30/10/19 and 19/2/20, during which 100 ventilated children were recruited. Children were identified by the lead clinician and data were collected on their underlying diagnosis, site of presumed infection, choice of antimicrobials and subsequent microbiology/virology results. The majority of children recruited were empirically started on IVAbs; however, only a small proportion was subsequently found to have a positive bacterial or fungal culture result. Based on this funding and the fact that it took 55 hours/120 hours to get a final negative endotracheal culture/blood culture result, the authors conclude that novel diagnostics are required in the PICU setting.

Although I agree with this final statement, I am far from convinced that the data presented in this study allows this conclusion to be reached.

The main issue I have with this study is that the authors appear to disregard the positive virology samples in their patients and appear to suggest that a negative bacterial culture is required to stop antibiotics. 52 of their admissions were thought to have a LRTI, of which at least 31 had an admission diagnosis of bronchiolitis. Of the 99 respiratory samples sent (ETT or NPA), 72 were positive for a viral pathogen and results were available between 21-24 hours. The principles of antimicrobial stewardship are summarised in START SMART then FOCUS. It is entirely reasonable to start antibiotics in an unwell child presenting with infection; however, it is crucial that at 48 hours, the child is reviewed with their microbiological and virology results, along with their inflammatory markers. The discussion presented within this paper makes it appear that there is little antimicrobial stewardship support available - it would be useful if the authors could clarify whether there is an antimicrobial stewardship service in their hospital. I am surprised by the discussion about needing to wait 120 hours for a final negative blood culture - although this is the time it may take to produce a final negative culture result, it is common practice amongst clinicians to review a blood culture at 48 hours and I am sure that the laboratory will issue a "negative at 48 hours" report. For this reason, I find this a rather disingenuous narrative to support the authors’ conclusion about the need for rapid tests.

Results: Patients with suspected and confirmed infection p4: "The most common indications for commencing antimicrobials within 48 hours of admission were suspected LRTI (52%), central nervous system (CNS) (29%) and bloodstream infection (19%)" Are these supposed to be percentages or absolute numbers. Table 2 suggests that these are absolute numbers with a denominator of 105 - all the percentages should then be slightly lower than stated.

Results: Although the authors provide results on the proportion of children admitted with LRTIs having subsequent positive bacteriology results, they do not subdivide this group into those with bronchiolitis (who are unlikely to have a secondary bacterial infection) and those with pneumonia. Of the 9 admissions with pneumonia, how many had a positive tracheal aspirate culture
(bacteriology)? How does this compare to the 57% positivity rate in children with VAPS?

Results: Performance of microbiology and virology investigations undertaken during PICU admission - p4 - paragraph 2 starts with a discussion about viral PCR results but then lists a set of bacterial pathogens. The authors provide no information about the site of these pathogens - are they all from tracheal aspirate samples or do they also include blood culture results?

AMR results: I think that table 7 is extremely unhelpful and adds very little to this manuscript. The study was not powered to identify an association between Ab use and AMR rates. If the authors are able to justify the inclusion of AMR data, I suggest that they report rates more conventionally ie MRSA, VRE, ESBLs and CREs (as opposed to trimethoprim resistant E Coli).

Discussion: In addition to the comments above, I wonder whether the authors should state that one of the reasons that only 17% of children being admitted with a LRTI is that most of them don’t have a bacterial infection (and have a confirmed virus instead). In the presence of a robust AMS service, I am not sure that having a rapid diagnostic panel should impact on duration of Ab prescribing in the majority of these children (and will not make any difference to the proportion started empirically on Abs).

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
No

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Antimicrobial stewardship and AMR

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.
John Clark, University of Cambridge, Cambridge, UK

The authors thank Dr Patel for his comments. These are addressed in turn:

The majority of children recruited were empirically started on IVAbs; however, only a small proportion was subsequently found to have a positive bacterial or fungal culture result. Based on this funding and the fact that it took 55 hours/120 hours to get a final negative endotracheal culture/blood culture result, the authors conclude that novel diagnostics are required in the PICU setting. Although I agree with this final statement, I am far from convinced that the data presented in this study allows this conclusion to be reached.

The main issue I have with this study is that the authors appear to disregard the positive virology samples in their patients and appear to suggest that a negative bacterial culture is required to stop antibiotics. 52 of their admissions were thought to have a LRTI, of which at least 31 had an admission diagnosis of bronchiolitis. Of the 99 respiratory samples sent (ETT or NPA), 72 were positive for a viral pathogen and results were available between 21-24 hours. The principles of antimicrobial stewardship are summarised in START SMART then FOCUS. It is entirely reasonable to start antibiotics in an unwell child presenting with infection; however, it is crucial that at 48 hours, the child is reviewed with their microbiological and virology results, along with their inflammatory markers. The discussion presented within this paper makes it appear that there is little antimicrobial stewardship support available - it would be useful if the authors could clarify whether there is an antimicrobial stewardship service in their hospital. I am surprised by the discussion about needing to wait 120 hours for a final negative blood culture - although this is the time it may take to produce a final negative culture result, it is common practice amongst clinicians to review a blood culture at 48 hours and I am sure that the laboratory will issue a "negative at 48 hours" report. For this reason, I find this a rather disingenuous narrative to support the authors' conclusion about the need for rapid tests.

In this institution, virology results are taken within the context of the patient, the severity of illness and other biochemical and microbiological tests. The present study only reports on children requiring mechanical ventilation in the PICU. Whilst the identification of a virus on a respiratory panel provides some reassurance as to the cause of illness, it is not definitive. This can be due to prolonged shedding of RNA as highlighted by reviewer 1, with the virus no longer active; the detection of a virus that is not actively contributing to a child's severe presentation (for example some presentations with rhinovirus or adenovirus), or there is a bacterial co-infection. Bacterial co-infection is common in children requiring mechanical ventilation for bronchiolitis. Preliminary reports are not typically available for microbiology culture of respiratory secretions hence information provided through diagnostic tests is limited in the setting of suspected respiratory infection. Clinical parameters are largely depended on to make antimicrobial decisions.

In terms of blood culture results, preliminary reports are available and there is a BacT/Alert system in the laboratory. Discussion -> paragraph 2 has been reworded to avoid confusion relating to timing of preliminary review of antimicrobials.

Support is available in this PICU for antimicrobial decision making. The manuscript has been updated to describe this (Methods -> Paragraph 4).
Results: Patients with suspected and confirmed infection p4: "The most common indications for commencing antimicrobials within 48 hours of admission were suspected LRTI (52%), central nervous system (CNS) (29%) and bloodstream infection (19%)". Are these supposed to be percentages or absolute numbers. Table 2 suggests that these are absolute numbers with a denominator of 105 - all the percentages should then be slightly lower than stated. These percentages reflect the proportion of patients treated for each of these problems within the first 48 hours of admission. There were some patients who did not receive a culture for the relevant problem described hence the discrepancy with table 2 which reports culture results versus treatment episodes.

Results: Although the authors provide results on the proportion of children admitted with LRTIs having subsequent positive bacteriology results, they do not subdivide this group into those with bronchiolitis (who are unlikely to have a secondary bacterial infection) and those with pneumonia. Of the 9 admissions with pneumonia, how many had a positive tracheal aspirate culture (bacteriology)? How does this compare to the 57% positivity rate in children with VAPS? Culture was much higher yield in children with VAP (5/7 (72%) culture positive) than those that received a culture at the time of admission for a primary lung infection. Of children that received a ETT culture within 48 hours of admission, 1/27 (3.7%) of bronchiolitis patients and 1/8 (12.5%) of those with bronchiolitis had a positive culture. A likely contributing factor is that 72% of all patients had antimicrobial administration prior to PICU admission. As per the aforementioned studies the expected bacterial co-infection rate in bronchiolitis may be as high as 37%.

Results: Performance of microbiology and virology investigations undertaken during PICU admission - p4 - paragraph 2 starts with a discussion about viral PCR results but then lists a set of bacterial pathogens. The authors provide no information about the site of these pathogens - are they all from tracheal aspirate samples or do they also include blood culture results? ‘On ETT aspirate culture’ added for clarity (Results -> Performance of microbiology and virology investigations undertaken during PICU admission -> Paragraph 2)

AMR results: I think that table 7 is extremely unhelpful and adds very little to this manuscript. The study was not powered to identify an association between Ab use and AMR rates. If the authors are able to justify the inclusion of AMR data, I suggest that they report rates more conventionally i.e., MRSA, VRE, ESBLs and CREs (as opposed to trimethoprim resistant E Coli). The table has been removed as per reviewer recommendation.

Discussion: In addition to the comments above, I wonder whether the authors should state that one of the reasons that only 17% of children being admitted with a LRTI is that most of them don't have a bacterial infection (and have a confirmed virus instead). In the presence of a robust AMS service, I am not sure that having a rapid diagnostic panel should impact on duration of Ab prescribing in the majority of these children (and will not make any difference to the proportion started empirically on Abs).
Addition of the following to the manuscript ‘Cultures may also be negative due to no bacteria being present, hence the value of fast turnaround highly sensitive tests for early cessation of antimicrobial therapy’ (Discussion -> Paragraph 3).

The authors agree that the impact of a highly sensitive multi-pathogen diagnostic panel is unknown in the PICU clinical setting as it is yet to be evaluated. This is the rationale behind the Rapid Assay for Sick Children for Acute Lung infection Study (RASCALS) at this institution (see BMJ Open protocol).¹ Given that most children admitted to PICU receive antimicrobial therapy empirically, this assay could be a first step to definitively inform rationalisation or cessation of therapy by ruling out bacterial infection. Whilst most lower respiratory tract infections may well be viral, in clinical practice, children who exhibit severe respiratory failure and/or signs of systemic inflammation or multi-organ disease continue to be treated with antimicrobials until bacterial infection is ruled out definitively. We hope assays such as the one we are evaluating will allow greater confidence for clinicians to de-escalate the use of antimicrobials.

1. Clark, J. A. et al. Rapid Assay for Sick Children with Acute Lung infection Study (RASCALS): diagnostic cohort study protocol. BMJ Open11, e056197 (2021).
2. Wiegers, H. M. G. et al. Bacterial co-infection of the respiratory tract in ventilated children with bronchiolitis; a retrospective cohort study. BMC Infect. Dis. 19, 938 (2019).
3. Thorburn, K., Harigopal, S., Reddy, V., Taylor, N. & van Saene, H. K. F. High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis. Thorax 61, 611 LP – 615 (2006).

**Competing Interests:** No competing interests were disclosed.
virological) diagnostics in this vulnerable population has not been described in such detail. 72 of 100 patients included in this study have received antibiotics before admission to the PICU. This may in part explain the low yield of bacterial cultures. The highest yield was found in respiratory (rt) PCR investigations for viral pathogens. Perhaps the authors should comment on:

- The quite long turnaround time of 22 hours for these PCRs
- The idea to perform point of care testing in this high acuity patients concerning the most important viral pathogens (such as influenza and RSV - beneath SARS-CoV-2 now)
- The fact, that not every positive PCR is confirmative for a causative role of this particular virus (e.g. due to the fact, that PCR results may be positive for weeks after primary infection in this age group)

Concerning the description of the epidemiology of the nosocomial infections, it would be informative to describe the rates per 1000 utilization days (BSI → central line days; VAP → days on mechanical ventilation) to make these results more comparable to other studies.

I do not totally agree with the statement on page 6, that “It is common practice to await microbiology results prior to cessation of antimicrobial therapy…” since the suspicion of a VAP may be questioned after 24 to 48 hours in patients with clinical and radiological signs which can be allocated to other reasons.

Tab. 6 differentiates between “Beta lactam”, carbapenem and cephalosporin although carbapenems and cephalosporins are betalactam antibiotics. It would be interesting to know, which antibiotics are summarized to “Beta Lactam” (Ampicillin-Sulbactam? Piperacillin with or without Tazobactam?)

Referring to the median age of the population and the nosocomial setting, it is unclear, why these children have received macrolides on 18.7% of all inpatient days. The low share of glycopeptides in Tab 6 contrasts with the detection of MRSA and MRSE in 8 patients (Tab 7). Have these patients received daptomycin or linezolid?

In addition, this list of resistant isolates contains 4 patients with Carbapenem-resistant Gram-negative Isolates. How were these patients treated?

Taken together, these are only minor points and I’d really appreciate if this study is republished soon after minor Revision.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
No source data required
Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Pediatric infectious diseases, Nosocomial infection in pediatric patients. Antimicrobial stewardship.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 28 Feb 2022

John Clark, University of Cambridge, Cambridge, UK

We thank Dr Simon for the review comments. Our responses to each point are listed below.

**The highest yield was found in respiratory (rt) PCR investigations for viral pathogens. Perhaps the authors should comment on:**
- The quite long turnaround time of 22 hours for these PCRs
- The idea to perform point of care testing in this high acuity patients concerning the most important viral pathogens (such as influenza and RSV - beneath SARS-CoV-2 now)
- The fact, that not every positive PCR is confirmative for a causative role of this particular virus (e.g. due to the fact, that PCR results may be positive for weeks after primary infection in this age group)

During and prior to the study, point of care PCR testing for respiratory pathogens was not available within the paediatric intensive care unit. This contributed to longer turnaround times than might be expected. Subsequent to the project, BioFire Respiratory 2.1 Panel testing (Biomérieux, France) has been introduced. This panel includes a target for SARS-CoV-2. In addition, the trust introduced Simple AMplification-Based Assay (SAMBA) II SARS-CoV-2 testing.

The authors agree that positive viral PCR detection does not necessarily confirm an underlying diagnosis due to prolonged RNA shedding after some pathogens are no longer causing symptoms or were an incidental finding.

**Concerning the description of the epidemiology of the nosocomial infections, it would be informative to describe the rates per 1000 utilization days (BSI → central line days; VAP → days on mechanical ventilation) to make these results more comparable to other studies.**

Rates of BSI and VAP have been added to the manuscript (Results -> Patients with suspected and confirmed infection). These rates need to be interpreted with caution due to variation in the definition used, particularly microbiological definitions, for these problems internationally. In this paper, we have included any instance of commencement or change of antimicrobial to treat for BSI or VAP.
I do not totally agree with the statement on page 6, that “It is common practice to await microbiology results prior to cessation of antimicrobial therapy…” since the suspicion of a VAP may be questioned after 24 to 48 hours in patients with clinical and radiological signs which can be allocated to other reasons.

This section has been reworded for clarity.

Tab. 6 differentiates between “Beta lactam”, carbapenem and cephalosporin although carbapenems and cephalosporins are beta-lactam antibiotics. It would be interesting to know, which antibiotics are summarized to “Beta Lactam” (Ampicillin-Sulbactam? Piperacillin with or without Tazobactam?)

Table 6 has been updated to classify antimicrobials more clearly. The most commonly used antimicrobial of the beta-lactams was ceftriaxone followed by piperacillin-tazobactam. Some subsequent courses of the same antimicrobial were noted by the lead author on repeating the analysis that were not included in the primary manuscript. This has been corrected in the present manuscript – apologies for this error that under reported antimicrobial use.

Referring to the median age of the population and the nosocomial setting, it is unclear, why these children have received macrolides on 18.7% of all inpatient days.

There were two main indications for macrolide treatment. Clarithromycin was given for 114 PICU days as a second agent to cover for atypical severe respiratory infection. There were 43 PICU treatment days with azithromycin, and this agent is sometimes used in this region as prophylaxis in children with chronic lung disease with recurrent respiratory infection.

The low share of glycopeptides in Tab 6 contrasts with the detection of MRSA and MRSE in 8 patients (Tab 7). Have these patients received daptomycin or linezolid? In addition, this list of resistant isolates contains 4 patients with Carbapenem-resistant Gram-negative Isolates. How were these patients treated?

MRSA was detected on routine screening tests in (Study ID 033, 099 and 101). In this centre, patients receive standard decolonisation treatment with mupirocin. No patients in the cohort received daptomycin. Linezolid was used for one patient (Study ID 046) for treatment of presumed CNS infection in the setting of status epilepticus and a ventriculoperitoneal shunt. This was due to previous red man syndrome in response to vancomycin.

Study ID 32 – had an AmpC producing Citrobacter freundii on ETT aspirate culture. This was sensitive to ciprofloxacin, gentamicin and meropenem and resistant to amoxicillin-clavulanate. After seven days of piperacillin-tazobactam, treatment was switched to meropenem which was given for eight days.

Study ID 73 – Pseudomonas aeruginosa grew on ETT aspirate culture which was resistant to ceftazidime and piperacillin-tazobactam but sensitive to meropenem. Treatment was changed from piperacillin-tazobactam to meropenem accordingly.
Study ID 79 – An AmpC producing *Enterobacter cloacae* was grown on ETT aspirate culture. This isolate was resistant to cefotaxime, ceftazidime, ertapenem, piperacillin-tazobactam and aztreonam. It was sensitive to ciprofloxacin and gentamicin. This patient received four days of ceftriaxone and three days of fluconazole in PICU before being discharged to the ward due to clinical improvement, prior to microbiology results becoming available.

Study ID 81 – This patient had an AmpC producing *Enterobacter cloacae* on ETT aspirate culture. This was resistant to cefotaxime, piperacillin-tazobactam, aztreonam, ceftazidime and ertapenem. It was sensitive to ciprofloxacin, gentamicin and meropenem. This was initially treated with six days of ceftriaxone and clarithromycin and was changed to an eight day course of meropenem after sensitivity results.

Study ID 88 – This patient had persistent growth of multi-resistant *Pseudomonas aeruginosa* on ETT aspirate culture. Resistance included ciprofloxacin, meropenem and piperacillin-tazobactam but there was sensitivity to ceftolozane. This patient received 10 different antibiotics during their admission, however the core treatment received was 33 days of tobramycin, 17 days of ceftolozane, 11 days of ciprofloxacin and eight days of colomycin.

The data presented only records antimicrobials administered during PICU admission – not the subsequent administration following stepdown to the ward. Treatment after PICU admission was not evaluated due to a large proportion of children being transferred back to their local hospital. The authors did not have access to these medical records. The overall effect of this is that the overall duration of glycopeptide treatment is lower than might be expected.

**Competing Interests:** No competing interests were disclosed.